Drug Trial Radar · NCT07807644
A Clinical Trial of GRT7040 in Adults With Acute Pain Following Bunionectomy
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Grünenthal GmbHIndustry
- Sponsor type
- Industry
- First posted
- Sep 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 clinical trial of GRT7040, currently being developed for the treatment of moderate-to-severe acute pain. The primary purpose of this trial is to assess efficacy and safety of GRT7040 compared with placebo in adult participants with acute pain following bunionectomy. The trial will compare three different doses of GRT7040 given from Day 1 until Day 3 (eg, 48 h after the first investigational medicinal product \[IMP\] administration) of GRT7040 or placebo.
Conditions
- Acute Pain
- Bunionectomy
Interventions
GRT7040Drug
The trial will compare three different doses of GRT7040 (Low, Medium \[Mid\] and High doses)
Hydrocodone bitartrate/ acetaminophen (HB/APAP)Drug
Reference drug
Placebo (matched to HB/APAP)Drug
Dummy treatment
Placebo (matched to GRT7040)Drug
Dummy treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time-Weighted Sum of Pain Intensity Difference From 0 to 48 Hours (SPID48)Time frame: Baseline to 48 hours after first dose of IMP
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.